Alyssa Pereslete

Featured in: Favicon

nature.com Favicon

cancernetwork.com Favicon

academic.oup.com

Articles

Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival

Aug 30, 2024 | academic.oup.com | Herbert Wertheim College |Alyssa Pereslete |Melissa Hughes |Nancy Lin

There are limited data regarding HER2-low expression dynamics between matched primary tumors and brain metastases (BrMs) in breast cancer. HER2-low expression has emerged as a new therapeutic biomarker for highly active antibody-drug conjugates with emerging intracranial activity. Patients with metastatic breast cancer (MBC) and BrMs seen at an NCI-designated center between 2003-2023 were identified.
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial | Nature Communications

Mar 19, 2024 | nature.com | Ann H. Partridge |Beth Overmoyer |Nabihah Tayob |Sara M. Tolaney |Qingchun Jin |Alyssa Pereslete | +1 more

AbstractThe landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-label trial (NCT02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →